University of North Carolina

Equitable Excellence℠ Scholarships Awarded to 200 Graduating High School Seniors

Retrieved on: 
Tuesday, June 6, 2023

Of the 200 scholarship recipients, half will receive $5,000 renewable scholarships, which will support them throughout all four years of their undergraduate study.

Key Points: 
  • Of the 200 scholarship recipients, half will receive $5,000 renewable scholarships, which will support them throughout all four years of their undergraduate study.
  • The other half will receive one-time $2,500 scholarships that can help them underwrite the immediate costs associated with higher education, such as tuition, books or fees.
  • Of the 200 students awarded with an Equitable Excellence Scholarship in 2023, 41 received the scholarship through Common App, up from just two students who received the scholarship through Common App in 2022.
  • The Equitable Excellence Scholarship is supported through a strategic partnership with Scholarship America , who selects scholarship recipients based on the criteria Equitable establishes.

Rescue Village announces the appointment of six new board members.

Retrieved on: 
Friday, June 9, 2023

CLEVELAND and AKRON, Ohio, June 9, 2023 /PRNewswire/ -- Rescue Village appointed six new members to the board of trustees, bringing the total number of trustees to sixteen.

Key Points: 
  • CLEVELAND and AKRON, Ohio, June 9, 2023 /PRNewswire/ -- Rescue Village appointed six new members to the board of trustees, bringing the total number of trustees to sixteen.
  • These additions to the Board of Trustees come at a pivotal time as Rescue Village prepares for its next strategic planning process and the enhanced programs and new projects that will follow.
  • Board of Trustees President Carrie Radivoyevitch stated, "I'm thrilled to welcome this extraordinary group of professionals to Rescue Village's board.
  • Not only are they highly skilled, but they also bring different perspectives and a common passion for Rescue Village's mission.

No Barriers Announces Executive Director

Retrieved on: 
Monday, June 5, 2023

FORT COLLINS, Colo., June 5, 2023 /PRNewswire/ -- No Barriers is pleased to welcome Pat Murray as Executive Director, as Interim Executive Director Sherri Kroonenberg joins the No Barriers Board of Directors, effective June 5. The onboarding of Murray will support No Barriers' vision and continued growth in providing transformative experiences that shift mindsets to sidelined communities.

Key Points: 
  • Pat Murray to serve as  Executive Director; Board of Directors welcomes Sherri Kroonenberg
    FORT COLLINS, Colo., June 5, 2023 /PRNewswire/ -- No Barriers is pleased to welcome Pat Murray as Executive Director, as Interim Executive Director Sherri Kroonenberg joins the No Barriers Board of Directors, effective June 5.
  • Pat Murray to serve as No Barriers Executive Director; Board of Directors welcomes Sherri Kroonenberg
    Kroonenberg joined No Barriers in 2022.
  • "We are extremely appreciative to Sherri for her authentic, strategic leadership and invaluable dedication to No Barriers," said Steve Clouthier, Chair of the No Barriers Board of Directors.
  • "I extend my heartfelt appreciation to the No Barriers community for your trust to bring about positive change through my leadership."

AACSB International Appoints Lily Bi as President and CEO

Retrieved on: 
Thursday, June 1, 2023

TAMPA, Fla., June 1, 2023 /PRNewswire/ -- AACSB International (AACSB), the world's largest and longest standing business education network and premier global accreditor announced the appointment of Lily Bi as its President and CEO, effective June 26, 2023.

Key Points: 
  • TAMPA, Fla., June 1, 2023 /PRNewswire/ -- AACSB International (AACSB), the world's largest and longest standing business education network and premier global accreditor announced the appointment of Lily Bi as its President and CEO, effective June 26, 2023.
  • "After an extensive search and meeting with several outstanding candidates, the AACSB CEO Search Committee has selected an innovative leader in Lily Bi, an accomplished association executive with global business expertise.
  • Lily Bi brings over 30 years of experience in strategy setting, global growth and development, internal audit, and technology innovation.
  • Beck-Dudley has served as AACSB's president and CEO for the past three years and was previously a long-time AACSB board member and volunteer.

AACSB International Appoints Lily Bi as President and CEO

Retrieved on: 
Thursday, June 1, 2023

TAMPA, Fla., June 1, 2023 /PRNewswire/ -- AACSB International (AACSB), the world's largest and longest standing business education network and premier global accreditor announced the appointment of Lily Bi as its President and CEO, effective June 26, 2023.

Key Points: 
  • TAMPA, Fla., June 1, 2023 /PRNewswire/ -- AACSB International (AACSB), the world's largest and longest standing business education network and premier global accreditor announced the appointment of Lily Bi as its President and CEO, effective June 26, 2023.
  • "After an extensive search and meeting with several outstanding candidates, the AACSB CEO Search Committee has selected an innovative leader in Lily Bi, an accomplished association executive with global business expertise.
  • Lily Bi brings over 30 years of experience in strategy setting, global growth and development, internal audit, and technology innovation.
  • Beck-Dudley has served as AACSB's president and CEO for the past three years and was previously a long-time AACSB board member and volunteer.

PDS Biotech Announces Interim Data Demonstrates 12-Month Survival Rate of 87% with PDS0101 in Combination with KEYTRUDA® (pembrolizumab) for Head and Neck Cancer Patients

Retrieved on: 
Thursday, May 25, 2023

FLORHAM PARK, N.J., May 25, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, announced promising interim data from the VERSATILE-002 (NCT04260126) Phase 2 clinical trial investigating PDS0101 in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with unresectable, recurrent or metastatic human papillomavirus (HPV)16-positive head and neck cancer. The results will be featured in a poster presentation and in a head and neck cancer expert panel discussion at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 2-6 in Chicago.

Key Points: 
  • In measuring the efficacy of PDS0101 in combination with KEYTRUDA®, the abstract highlights the following interim data:
    Median progression-free survival was 10.4 months (95% CI 4.2, 15.3).
  • Published results are median PFS of 2-3 months for approved ICIs when used as monotherapy in patients with similar PD-L1 levels*.
  • Confirmed and unconfirmed objective response rate was 41.2% (14/34 patients), which is identical to the preliminary response rate data PDS Biotech previously reported at ASCO 2022 (7/17 patients).
  • VERSATILE-002 is investigating two patient populations of HPV16-positive head and neck cancer patients whose cancer has returned or spread.

REGENXBIO Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RGX-121 Gene Therapy for Hunter Syndrome

Retrieved on: 
Tuesday, May 23, 2023

"I am encouraged by the FDA's recognition of the potential of a gene therapy like RGX-121 to improve the quality of life for boys with severe Hunter syndrome and the urgent need for new treatment options."

Key Points: 
  • "I am encouraged by the FDA's recognition of the potential of a gene therapy like RGX-121 to improve the quality of life for boys with severe Hunter syndrome and the urgent need for new treatment options."
  • "The expedited development of new treatment options like RGX-121 are critical to families facing this devastating diagnosis."
  • In addition, improvements in neurodevelopmental and daily activity skill acquisition were observed up to three years after RGX-121 administration.
  • A Phase I/II trial of RGX-121 for the treatment of pediatric patients with MPS II over the age of five years old is also ongoing.

The Wall Printer Selected for Excellence in Manufacturing and Distribution

Retrieved on: 
Wednesday, May 17, 2023

NEW YORK, May 17, 2023 /PRNewswire/ -- The Wall Printer (TWP), the only full service vertical printer firm based in North America, today announces it has been recognized as a winner in the Manufacturing & Distribution category by the Coastal Entrepreneur Awards .

Key Points: 
  • NEW YORK, May 17, 2023 /PRNewswire/ -- The Wall Printer (TWP), the only full service vertical printer firm based in North America, today announces it has been recognized as a winner in the Manufacturing & Distribution category by the Coastal Entrepreneur Awards .
  • The awards are organized by University of North Carolina Wilmington's Center for Innovation and Entrepreneurship and the Greater Wilmington Business Journal.
  • The 2023 program honors a total of 11 companies in categories ranging from technology, manufacturing, not-for-profit, to professional services.
  • Today, more than 120 new businesses have been established, trained and supported by The Wall Printer.

SELLAS Life Sciences to Host Virtual Expert Panel Discussion on GFH009 in Acute Myeloid Leukemia

Retrieved on: 
Tuesday, May 16, 2023

NEW YORK, May 16, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced it will host a virtual panel discussion on Tuesday, May 30, 2023 at 8:00 a.m. EST.

Key Points: 
  • NEW YORK, May 16, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced it will host a virtual panel discussion on Tuesday, May 30, 2023 at 8:00 a.m. EST.
  • GFH009 is a clinical stage small molecule, highly selective CDK9 inhibitor that SELLAS is investigating for treatment of patients with hematologic malignancies and solid tumors.
  • SELLAS plans to commence a Phase 2a clinical trial during the second quarter of 2023 with GFH009 in combination with venetoclax and azacitidine in AML patients.
  • A live question and answer session will follow the formal discussion and a replay of the event will be available on SELLAS’s website .

International Chinese Language Day Giant Panda Series Livestream Builds Bridge for Cultural Exchange

Retrieved on: 
Tuesday, April 25, 2023

CHENGDU, China, April 25, 2023 /PRNewswire/ -- April 20th this year marks the 14th United Nations Chinese Language Day, and also the 4th International Chinese Language Day jointly initiated by the Center for Language Education and Cooperation and Chinese Plus.

Key Points: 
  • CHENGDU, China, April 25, 2023 /PRNewswire/ -- April 20th this year marks the 14th United Nations Chinese Language Day, and also the 4th International Chinese Language Day jointly initiated by the Center for Language Education and Cooperation and Chinese Plus.
  • During the livestream session for American youngsters, the audiences watched the story about giant panda Tao Tao's survival in wilderness, and they left comments such as "I love Tao Tao!"
  • During the Oxford session, students eagerly participated in a knowledge competition about the giant panda, and they created their own stories about the animal using giant panda handicrafts they made themselves.
  • At present, the International Chinese Language Day has been held for four straight years, having garnered participation from some 150 million person/times from more than 150 nations across the planet.